← board
RNXT
RenovoRxdistress 5/10 · elevated risk$0.86-1%today-39% from 52w high
Oncology 1
Lead: locally advanced pancreatic cancer · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$14M
Runway
1.3 yrs
Shares 1y
+23%
Price & events
-15.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-2.4%
1W
-5.6%
1M
-4.4%
3M
-13.7%
6M
-32.3%
1Y
-30.6%
2Y
—
5Y
-88.2%
All
Overview
- Market Cap
- $38.79M
- Volume
- 2.73K
- 52 Week Range
- $0.73 – $1.40
- Total Shares
- 45.10M
- Float Shares
- 39.87M
- Short %
- 0.79%
- % Held by Insiders
- 3.42%
- % Held by Institutions
- 19.01%
- RVOL
- 0.01x
- Beta
- 0.99
Pipeline stages · 1 programs
Gemcitabine, nab-paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 3 | Gemcitabine, nab-paclitaxel | Locally Advanced Pancreatic Cancer | 190 | recruiting |
Catalyst news & presentations · 11
- 2027Guided 40%readoutPhase 3IAG (intra-arterial gemcitabine via RenovoCath) · Final data readout from Phase III TIGeR-PaC trialSEC 8-K
- 2027Guided 40%readoutPhase 3IAG (gemcitabine via RenovoCath) · Final topline data from Phase III TIGeR-PaC trial expected in 2027.SEC 8-K
- middle of 2026enrollment completesecondaryPhase 3IAG (gemcitabine via RenovoCath) · Anticipated completion of enrollment in Phase III TIGeR-PaC trial.SEC 8-K
- early 2026enrollment completesecondaryPhase 3IAG (intra-arterial gemcitabine via RenovoCath) · Enrollment completion for Phase III TIGeR-PaC trialSEC 8-K
- second half of 2025readoutPhase 3Data Monitoring Committee recommendation on whether to continue studySEC 8-K
- during 2025enrollment completesecondaryPhase 3RenovoCath · Full enrollment of Phase III TIGeR-PaC trial (114 patients)SEC 8-K
- during 2025enrollment completesecondaryPhase 3Full enrollment of TIGeR-PaC trialSEC 8-K
- third quarter of 2025readoutPhase 3RenovoCath · Data Monitoring Committee review of second interim analysis for TIGeR-PaC trialSEC 8-K
- second quarter of 2025readoutPhase 3Second interim analysis triggered by 52nd eventSEC 8-K
- late 2024 or early 2025readoutPhase 3gemcitabine HCl · Second interim analysis of TIGeR-PaC trial triggered by 52nd eventSEC 8-K
- 2024-09-25partnershipRenovoCath · Expanded manufacturing relationship with Medical Murray; warrant issuedSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-01Ascendiant CapitalBuy
- 2026-04-09Ascendiant CapitalBuy
- 2026-04-08HC Wainwright & Co.Buy
- 2026-02-17Ascendiant CapitalBuy
- 2025-11-21Ascendiant CapitalBuy
- 2025-08-25Ascendiant CapitalBuy
Competitors — locally advanced pancreatic cancer
Recent news
- 2026-07-22RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates - MSN
- 2026-07-20Nextpower Completes Acquisition of Prevalon Energy, Launches Advanced Energy Storage Business - Business Wire
- 2026-07-16Elutia Signs Definitive Agreement to Sell SimpliDerm® in - GlobeNewswire
- 2026-07-14RenovoRx Inc. (RNXT) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Progress Remains Key Focus - High Estimate Range - DonanımHaber
- 2026-07-09Crane NXT Announces Dates for Second Quarter 2026 Earnings Release and Earnings Call - GlobeNewswire
- 2026-07-09Nextpower to Announce First Quarter Fiscal 2027 Financial Results on July 30, 2026 - Business Wire
- 2026-07-02RenovoRx Receives Nasdaq Delisting Notice: Key Details from Latest 8-K Filing - Minichart
- 2026-07-02RenovoRx Received Notice of Noncompliance - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.